Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Tickers RETA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.